ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 110 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $764,168 | -37.9% | 376,437 | -29.6% | 0.00% | – |
| Q2 2023 | $1,229,780 | -35.2% | 534,687 | -14.7% | 0.00% | – |
| Q1 2023 | $1,899,189 | +9.2% | 626,795 | -16.0% | 0.00% | – |
| Q4 2022 | $1,738,753 | +29.2% | 746,246 | +5.8% | 0.00% | – |
| Q3 2022 | $1,346,000 | -62.8% | 705,062 | -47.2% | 0.00% | – |
| Q2 2022 | $3,619,000 | -32.3% | 1,335,425 | -25.6% | 0.00% | – |
| Q1 2022 | $5,348,000 | -64.8% | 1,794,865 | -54.0% | 0.00% | – |
| Q4 2021 | $15,184,000 | +88.6% | 3,903,230 | +108.0% | 0.00% | – |
| Q3 2021 | $8,049,000 | +137.5% | 1,876,103 | +67.7% | 0.00% | – |
| Q2 2021 | $3,389,000 | -26.3% | 1,118,577 | -19.0% | 0.00% | – |
| Q1 2021 | $4,597,000 | -66.6% | 1,380,511 | -64.4% | 0.00% | -100.0% |
| Q4 2020 | $13,758,000 | +566.9% | 3,875,326 | +488.0% | 0.00% | – |
| Q3 2020 | $2,063,000 | +4110.2% | 659,038 | +2368.3% | 0.00% | – |
| Q2 2020 | $49,000 | -73.4% | 26,700 | -85.3% | 0.00% | – |
| Q1 2020 | $184,000 | -52.9% | 182,108 | +29.6% | 0.00% | – |
| Q4 2019 | $391,000 | +1855.0% | 140,546 | +982.7% | 0.00% | – |
| Q3 2019 | $20,000 | -95.4% | 12,981 | -93.7% | 0.00% | – |
| Q2 2019 | $431,000 | +6.7% | 207,529 | +83.8% | 0.00% | – |
| Q1 2019 | $404,000 | +220.6% | 112,900 | +245.3% | 0.00% | – |
| Q4 2018 | $126,000 | -70.1% | 32,700 | -26.8% | 0.00% | – |
| Q3 2018 | $422,000 | -37.5% | 44,700 | -51.7% | 0.00% | – |
| Q2 2018 | $675,000 | -19.5% | 92,500 | -44.8% | 0.00% | – |
| Q1 2018 | $839,000 | +376.7% | 167,700 | +379.2% | 0.00% | – |
| Q4 2017 | $176,000 | -39.9% | 34,999 | -25.9% | 0.00% | – |
| Q3 2017 | $293,000 | +40.2% | 47,220 | -18.7% | 0.00% | – |
| Q2 2017 | $209,000 | +59.5% | 58,079 | +44.2% | 0.00% | – |
| Q1 2017 | $131,000 | -80.2% | 40,272 | -85.1% | 0.00% | – |
| Q4 2016 | $661,000 | +54.1% | 269,939 | +116.6% | 0.00% | – |
| Q3 2016 | $429,000 | +41.1% | 124,603 | +42.5% | 0.00% | – |
| Q2 2016 | $304,000 | +79.9% | 87,424 | +113.6% | 0.00% | – |
| Q1 2016 | $169,000 | -30.2% | 40,935 | -24.8% | 0.00% | – |
| Q4 2015 | $242,000 | -71.3% | 54,400 | -60.7% | 0.00% | – |
| Q3 2015 | $843,000 | – | 138,282 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |